Skip to main content
Top
Published in: Clinical and Translational Oncology 9/2020

01-09-2020 | Metastasis | Research Article

DNA damage response proteins and its role in tumor progression of uveal melanoma with patient outcome

Authors: S. Kashyap, J. Jha, M. K. Singh, L. Singh, S. Sen, J. Kaur, M. S. Bajaj, N. Pushker

Published in: Clinical and Translational Oncology | Issue 9/2020

Login to get access

Abstract

Background

The role of DNA damage response (DDR) proteins is poorly understood in uveal melanoma. ATR belongs to one of those proteins that induce DDR by arresting the cell cycle which leads to DNA repair. ATR is localized at position 23 on the same chromosome 3 where BAP1 is located at position 21.1 which is a known poor prognostic marker of UM. The aim of our study is to detect the expression of ATR at the protein and RNA levels and determine its prognostic significance.

Methods

Expression of nuclear ATR was investigated on sixty-nine UM patients. Formalin-fixed paraffin-embedded choroidal melanoma samples were taken to evaluate the expression of ATR. Fifty samples were also validated by real-time PCR. Results of both protein and mRNA were then correlated with clinicopathological parameters. To determine the prognostic significance, Kaplan–Meier and multivariate analyses were performed.

Results

Loss of ATR protein was seen in 72% cases which was statistically significant with epithelioid cell type (p = 0.005), tumor thickness (p = 0.016), mitotic figures (p = 0.001) and BAP1 loss (p < 0.001). At the transcriptional level loss of ATR was seen in 76% cases which were statistically significant with metastasis (p = 0.046), staging (0.044) and loss of BAP1 (p = 0.022). On multivariate analysis loss of ATR and tumor staging came out to be independent prognostic parameters.

Conclusion

Our data suggest that ATR might serve as a potential prognostic marker in UM patients and could serve as a potential therapeutic target.
Literature
1.
go back to reference Singh M, Durairaj P, Yeung J. Uveal melanoma: a review of the literature. Oncol Ther. 2018;6:87–104.CrossRef Singh M, Durairaj P, Yeung J. Uveal melanoma: a review of the literature. Oncol Ther. 2018;6:87–104.CrossRef
2.
go back to reference O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60:547–60.CrossRef O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60:547–60.CrossRef
3.
go back to reference Harbour JW, Onken MD, Roberson EDO, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410–3.CrossRef Harbour JW, Onken MD, Roberson EDO, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410–3.CrossRef
5.
go back to reference Eletr ZM, Yin L, Wilkinson KD. BAP1 is phosphorylated at serine 592 in S-phase following DNA damage. FEBS Lett. 2013;587:3906–11.CrossRef Eletr ZM, Yin L, Wilkinson KD. BAP1 is phosphorylated at serine 592 in S-phase following DNA damage. FEBS Lett. 2013;587:3906–11.CrossRef
6.
go back to reference Fokas E, Prevo R, Hammond EM, et al. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev. 2013;40:109–17.CrossRef Fokas E, Prevo R, Hammond EM, et al. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev. 2013;40:109–17.CrossRef
7.
go back to reference Menezes DL, Holt J, Tang Y, et al. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function. Mol Cancer Res. 2015;13:120–9.CrossRef Menezes DL, Holt J, Tang Y, et al. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function. Mol Cancer Res. 2015;13:120–9.CrossRef
8.
go back to reference Tanaka A, Weine S, Nagy N, et al. Germline mutation in ATR in autosomal-dominant oropharyngeal cancer syndrome. AJHG. 2012;90:511–7.CrossRef Tanaka A, Weine S, Nagy N, et al. Germline mutation in ATR in autosomal-dominant oropharyngeal cancer syndrome. AJHG. 2012;90:511–7.CrossRef
9.
go back to reference Bertoni F, Codegoni AM, Furlan D, et al. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer. 1999;26:176–80.CrossRef Bertoni F, Codegoni AM, Furlan D, et al. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer. 1999;26:176–80.CrossRef
10.
go back to reference Menoyo A, Alazzouzi H, Espín E, et al. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res. 2001;61:7727–30.PubMed Menoyo A, Alazzouzi H, Espín E, et al. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res. 2001;61:7727–30.PubMed
11.
go back to reference Lewis KA, Mullany S, Thomas B, et al. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. Cancer Res. 2005;65:7091–5.CrossRef Lewis KA, Mullany S, Thomas B, et al. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. Cancer Res. 2005;65:7091–5.CrossRef
12.
go back to reference van Essen TH, van Pelt SI, Versluis M, et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol. 2014;98:1738–43.CrossRef van Essen TH, van Pelt SI, Versluis M, et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol. 2014;98:1738–43.CrossRef
13.
go back to reference Chen CF, Ruiz-Vega R, Vasudeva P, et al. ATR mutations promote the growth of melanoma tumors by modulating the immune microenvironment. Cell Rep. 2017;18:2331–42.CrossRef Chen CF, Ruiz-Vega R, Vasudeva P, et al. ATR mutations promote the growth of melanoma tumors by modulating the immune microenvironment. Cell Rep. 2017;18:2331–42.CrossRef
14.
go back to reference Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989–98.CrossRef Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989–98.CrossRef
15.
go back to reference Diniz MG, Silva Jde F, de Souza FT, et al. Association between cell cycle gene transcription and tumor size in oral squamous cell carcinoma. Tumour Biol. 2015;36:9717–22.CrossRef Diniz MG, Silva Jde F, de Souza FT, et al. Association between cell cycle gene transcription and tumor size in oral squamous cell carcinoma. Tumour Biol. 2015;36:9717–22.CrossRef
16.
go back to reference Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11:255–63.CrossRef Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11:255–63.CrossRef
17.
go back to reference McLean MJ, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 1977;95:48–58.CrossRef McLean MJ, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 1977;95:48–58.CrossRef
18.
go back to reference de la Cruz PO, Jr Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65:112–5.CrossRef de la Cruz PO, Jr Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65:112–5.CrossRef
19.
go back to reference Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389–98.CrossRef Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389–98.CrossRef
20.
go back to reference Bujara K. Necrotic malignant melanomas of the choroid and ciliary body. A clinicopathological and statistical study. Graefes Arch Clin Exp Ophthalmol. 1982;219:40–3.CrossRef Bujara K. Necrotic malignant melanomas of the choroid and ciliary body. A clinicopathological and statistical study. Graefes Arch Clin Exp Ophthalmol. 1982;219:40–3.CrossRef
21.
go back to reference Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 2008;130:1091–103.CrossRef Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 2008;130:1091–103.CrossRef
22.
go back to reference Zighelboim I, Schmidt AP, Gao F, et al. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol. 2009;27:3091–6.CrossRef Zighelboim I, Schmidt AP, Gao F, et al. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol. 2009;27:3091–6.CrossRef
Metadata
Title
DNA damage response proteins and its role in tumor progression of uveal melanoma with patient outcome
Authors
S. Kashyap
J. Jha
M. K. Singh
L. Singh
S. Sen
J. Kaur
M. S. Bajaj
N. Pushker
Publication date
01-09-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02281-x

Other articles of this Issue 9/2020

Clinical and Translational Oncology 9/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine